Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

• Status: RECRUITING
• Trial end date: 2029-12-01

Summary

This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom

• Phase: PHASE3

Details

• Lead Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
• Treatments: Gemcitabine; Lenalidomide; Oxaliplatin; Rituximab; tafasitamab